Clinical trial NCT03359070: Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris
Official title: Clinical Study of Non-inferiority (Phase 2), Comparing Dapaconazole (BL123 - Biolab Sanus Farmacêutica Ltda.) Versus Miconazole Nitrate (União Química) in Patients With a Single Lesion of Tinea Cruris.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Tinea Cruris
Keywords: Tinea cruris
dapaconazole
topical antifungal
dermatophytoses
Lead sponsor: Galeno Desenvolvimento de Pesquisas Clínicas
Sponsor class: OTHER_GOV
Collaborators: name: Biolab Sanus Farmaceutica
First posted: 2017-12-02
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial aims to evaluate the efficacy of dapaconazole tosylate 2% cream in the treatment of Tinea cruris compared to the active control miconazole nitrate 2% cream in patients with a single lesion.

Detailed description: This is a phase 2, non-inferiority, monocentric, double-blind, randomized (allocation of treatment), balanced, controlled (active comparator) trial, with two parallel groups.

Randomization depended on inclusion/exclusion criteria, taking into account the confirmation of diagnosis by the direct mycological test and culture performed during the screening phase.

Participants showed up to the clinic, for treatment, during 14 consecutive days, when one of the investigational products (according to the randomization) was applied by a blind member of the study staff. A non-blind member of the study staff weighed the corresponding investigational product and passed on to the blind member only a spatula with the weighed product, in order to maintain the blinded aspect of the trial.

For exploratory purposes, clinical and mycological evaluations was also performed after 7 and after 14 days of treatment.

Safety analysis was performed considering all the randomized patients to which at least one dose of the investigational products has been applied, regardless of the result of the fungal culture.

Conclusion of non-inferiority was based on the per protocol set. It was deemed as per protocol those participants who did not miss more than 20% of the applications and, also, no more than four consecutive application days.

Eligibility criteria: Inclusion Criteria:

* Participants aged from 18 to 65 years old, male, or female with no childbearing potential or who are using an effective contraceptive method and who do not plan to become pregnant during the study period.
* Presence of dermatological lesion of Tinea cruris, with an area not exceeding 8 cm², having, also, the diagnosis confirmed by direct mycological (KOH) test and fungus culture.
* No previous treatment with antimycotic medication for the current dermatologic lesion.
* No evidence of other significant diseases, that, at the investigator's discretion, may affect the participation in the clinical trial, in accordance with the protocol requirements.
* Ability to understand the nature and the objective of the clinical trial, including the risks and possible side effects; intention to cooperate with the investigator and act in accordance with the protocol requirements, as confirmed by the informed consent form signature.

Exclusion Criteria:

* Known hypersensitivity to miconazole or to chemically related compounds (azoles) or to the compounds of the investigational products.
* Existing hepatic and/or renal diseases or other pathologic findings, which might interfere with the safety and tolerability of the active ingredients.
* Screening laboratory tests presenting deviations deemed as clinically significant, which, due to possible risks, prevents the participation in clinical trial.
* Treatment, within 3 months prior to the start of the clinical trial treatment, with any drug known to have a well-established toxic potential to major organs.
* Pregnant or lactating women
* Participation in any clinical trial, or intake of any investigational product, within the last six months prior to the inclusion in the clinical trial.
* History of drug addiction.
* Any prior treatment for the present lesion which, at investigator discretion, may interfere with the objectives of the clinical trial.
* Participants who has any condition that prevents him from participating in the study according to the investigator's judgment.

Primary outcomes:
measure: Proportion of participants with therapeutic cure.
timeFrame: 14 days of treatment
Secondary outcomes:
measure: Number of days until clinical cure
timeFrame: up to 14 days
measure: Number of adverse events per participant
timeFrame: up to 30 days
Other outcomes:
Locations:
city: Campinas
country: Brazil
facility: Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME
state: SP
Study officials:
References: